209 related articles for article (PubMed ID: 24612620)
1. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Rahbari NN; Reissfelder C; Schulze-Bergkamen H; Jäger D; Büchler MW; Weitz J; Koch M
BMC Cancer; 2014 Mar; 14():174. PubMed ID: 24612620
[TBL] [Abstract][Full Text] [Related]
2. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
[TBL] [Abstract][Full Text] [Related]
3. Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
Pan Z; Peng J; Lin J; Chen G; Wu X; Lu Z; Deng Y; Zhao Y; Sui Q; Wan D
Cancer Commun (Lond); 2018 May; 38(1):29. PubMed ID: 29843800
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
6. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Loupakis F; Falcone A
Nat Rev Clin Oncol; 2010 Apr; 7(4):190-1. PubMed ID: 20354542
[TBL] [Abstract][Full Text] [Related]
9. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
[TBL] [Abstract][Full Text] [Related]
12. Multicentre study of perioperative
Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Chan KM; Chiang JM; Lee CF; Yu MC; Lee WC; Chen JS; Wang JY
World J Surg Oncol; 2011 Dec; 9():174. PubMed ID: 22208884
[TBL] [Abstract][Full Text] [Related]
15. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.
Maruyama K; Tominaga T; Nonaka T; Moriyama M; Oyama S; Ishii M; Sawai T; Nagayasu T
Int J Colorectal Dis; 2022 Jul; 37(7):1545-1552. PubMed ID: 35624174
[TBL] [Abstract][Full Text] [Related]
18. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Kataoka K; Kanazawa A; Iwamoto S; Kato T; Nakajima A; Arimoto A
World J Surg; 2014 Apr; 38(4):936-46. PubMed ID: 24166026
[TBL] [Abstract][Full Text] [Related]
19. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
